Advertisement

AAPS PharmSciTech

, Volume 11, Issue 2, pp 558–562 | Cite as

Polymer Percolation Threshold in HPMC Extended Release Formulation of Carbamazepine and Verapamil HCl

  • Tamara Gonçalves-Araújo
  • Ali R. Rajabi-Siahboomi
  • Isidoro Caraballo
Research Article

Abstract

The principles of the percolation theory were applied to further understand and design hydroxypropyl methylcellulose (HPMC) extended release matrix tablets containing carbamazepine and verapamil HCl. This statistical theory studies disordered or chaotic systems where the components are randomly distributed in a lattice. The application of this theory to study the hydration and drug release of hydrophilic matrices allows describing the changes in hydration and drug release kinetics of swellable matrices. The aim of this work was to study and develop extended release matrix formulations for carbamazepine and verapamil HCl, containing hypromellose (HPMC, METHOCEL™ Premium K100M CR) as rate controlling polymer using the concepts of percolation theory. The knowledge of the percolation threshold of the components of the matrix formulations contributes to improve their design. First, reducing the time to market and second, avoiding to formulate in the nearby of the percolation threshold, which will result in a lower variability. Therefore these formulations will be more robust when they are prepared at industrial scale. The HPMC percolation threshold for drugs with very different water solubilities was determined and it was shown that there was no significant influence of drug solubility on the HPMC critical concentration threshold (excipient percolation threshold). This may be related to the versatility and broad functionality of the swelling hydrophilic matrices.

Key words

carbamazepine extended release hydrophilic matrix hypromellose verapamil HCl percolation theory 

Notes

Acknowledgments

The authors wish to express their gratitude to Colorcon for funding this study and for the supply of METHOCEL™ and Recordatti for the supply of the carbamazepine and verapamil HCl.

References

  1. 1.
    Colombo P, Bettini R, Santi P, Peppas NA. Swellable matrices for controlled drug delivery: gel layer behavior, mechanism and optimal performance. Pharm Sci Tech Today. 2000;3:198–204.CrossRefGoogle Scholar
  2. 2.
    Varma M, Kaushal A, Garg A, Garg S. Factors affecting mechanism and kinetics of drug release from matrix-based oral controlled drug delivery systems. Am J Drug Del. 2004;2(1):43–57.CrossRefGoogle Scholar
  3. 3.
    Levina M, Rajabi-Siahboomi AR. The influence of excipients on drug release from hydroxypropyl methylcellulose matrices. J Pharm Sci. 2004;93(11):2746–54.CrossRefPubMedGoogle Scholar
  4. 4.
    Patel DM, Patel NM, Pandya NN, Jogani PD. Gastroretentive drug delivery system of carbamazepine: formulation optimization using simplex lattice design: a technical note. AAPSPharmSciTech. 2007;8(1):Article 11. doi:  10.1208/pt0801011
  5. 5.
    Passirini N, Perissutti B, Albertini B, Voinovich D, Moneghini M, Rodriguz L. Controlled release of verapamil hydrochloride from waxy microparticles prepared by spray congealing. J Control Release. 2003;88(2):263–75.CrossRefGoogle Scholar
  6. 6.
    Caraballo I, Millán M, Rabasco AM. Relationship between drug percolation threshold and particle size in matrix tablets. Pharm Res. 1996;13:387–90.CrossRefPubMedGoogle Scholar
  7. 7.
    Fuertes I, Miranda A, Millán M, Caraballo I. Estimation of the percolation thresholds in acyclovir hydrophilic matrix tablets. Eur J Pharm Biopharm. 2006;64:336–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Miranda A, Millán M, Caraballo I. Study of the critical points in the release and hydration kinetics of swellable matrix type controlled delivery systems. Int J Pharm. 2006;311:75–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Miranda A, Millán M, Caraballo I. Study of the critical points in lobenzarit disodium hydrophilic matrices for controlled drug delivery. Chem Pharm Bull. 2006;54(5):598–602.CrossRefPubMedGoogle Scholar
  10. 10.
    Miranda A, Millán M, Caraballo I. Investigation of the influence of particle size on the excipient percolation thresholds of HPMC hydrophilic matrix tablets. J Pharm Sci. 2007;96:2745–56.CrossRefGoogle Scholar
  11. 11.
    Gonçalves-Araújo T, Rajabi-Siahboomi AR, Caraballo I. Application of percolation theory in the study of an extended release verapamil hydrochloride formulation. Int J Pharm. 2008;361:112–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Leuenberger H, Leu R, Bonny JD. Application of percolation theory and fractal geometry to tablet compaction. Drug Dev Ind Pharm. 1992;18:6723–766.CrossRefGoogle Scholar
  13. 13.
    Ford JL, Mitchell K, Rowe P, Armstrong DJ, Elliot PNC, Rostron C et al. Mathematical modelling of drug release from hydroxypropylmethylcelluose matrices: effect of temperature. Int J Pharm. 1991;71:95–104.CrossRefGoogle Scholar
  14. 14.
    Stauffer D, Aharony A (1992) Introduction to percolation theory, 2nd ed., Francis, London, Washington, DC.Google Scholar
  15. 15.
    Leuenberger H, Rohera BH, Haas C. Percolation theory—a novel approach to solid dosage form design. Int J Pharm. 1987;38:109–15.CrossRefGoogle Scholar
  16. 16.
    Millán M, Caraballo I, Rabasco A. The role of the drug/excipient particle size ratio in the percolation model for tablets. Pharm Res. 1998;15(2):220–4.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2010

Authors and Affiliations

  • Tamara Gonçalves-Araújo
    • 1
    • 2
  • Ali R. Rajabi-Siahboomi
    • 3
  • Isidoro Caraballo
    • 1
  1. 1.Department of Pharmacy and Pharmaceutical Technology, Faculty of PharmacyUniversity of SevilleSevilleSpain
  2. 2.Department of Pharmacy and Pharmaceutical Technology, Faculty of PharmacyFederal University of CearáFortalezaBrazil
  3. 3.Colorcon Ltd.West PointUSA

Personalised recommendations